多西他赛对比最佳支持治疗在既往接受铂类化疗的非小细胞肺癌患者中的前瞻性随机试验
本研究纳入既往接受过铂类化疗的IIIB/IV期非小细胞肺癌患者,随机分配至多西他赛100 mg/m2组(49例)、75 mg/m2组(55例)或最佳支持治疗组,评估生存、缓解、毒性和生活质量。多西他赛组至进展时间和中位生存均优于最佳支持治疗组,75 mg/m2组差异更显著,但100 mg/m2组出现发热性中性粒细胞减少并导致3例死亡。结论认为多西他赛可显著延长生存,75 mg/m2剂量下获益大于风险。
要点
- 多西他赛组至进展时间较最佳支持治疗组延长(10.6 vs 6.7周,P<.001)。
- 多西他赛75 mg/m2组中位生存较对应最佳支持治疗组延长(7.5 vs 4.6个月,P=.010)。
- 多西他赛100 mg/m2组发生发热性中性粒细胞减少11例,其中3例死亡。
核心结论
- 多西他赛治疗与生存期显著延长相关,在75 mg/m2剂量下,多西他赛治疗的获益大于风险。
研究设计与样本
- 前瞻性随机试验,纳入体能状态0-2、IIIB/IV期、既往接受过一种或以上铂类化疗方案的非小细胞肺癌患者。
- 排除有症状脑转移或既往接受过紫杉醇治疗的患者,按体能状态和对顺铂化疗的最佳缓解进行分层。
- 患者随机分配至多西他赛100 mg/m2组(49例)、多西他赛75 mg/m2组(55例)或最佳支持治疗组,每3周评估一次。
- 共104例患者入组,其中103例符合入组条件,各组预后因素均衡。
主要发现
- 在84例可测量病灶患者中,6例(7.1%)达到部分缓解,两个剂量组各3例。
- 多西他赛组至进展时间较最佳支持治疗组延长(10.6 vs 6.7周,P<.001)。
- 多西他赛组中位生存较最佳支持治疗组延长(7.0 vs 4.6个月,log-rank检验P=.047)。
- 多西他赛75 mg/m2组中位生存较对应最佳支持治疗组延长(7.5 vs 4.6个月,log-rank检验P=.010),1年生存率分别为37%和11%(χ2检验P=.003)。
- 多西他赛100 mg/m2组发生发热性中性粒细胞减少11例,其中3例死亡;多西他赛75 mg/m2组发生1例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum-based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life. UNLABELLED: PATIENTS AND METHODS: Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer with either measurable or evaluable lesions were eligible for entry onto the study if they had undergone one or more platinum-based chemotherapy regimens and if they had adequate hematology and biochemistry parameters. They were excluded if they had symptomatic brain metastases or if they had previously been treated with paclitaxel. Patients were stratified by performance status and best response to cisplatin chemotherapy and were then randomized to treatment with docetaxel 100 mg/m2 (49 patients) or 75 mg/m2 (55 patients) or best supportive care. Patients in both arms were assessed every 3 weeks. RESULTS: One hundred four patients (103 of whom were eligible for entry onto the study) were well balanced for prognostic factors. Of 84 patients with measurable lesions, six (7.1%) achieved partial responses (three patients at each dose level). Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P < .001), as was median survival (7.0 v 4.6 months; log-rank test, P = .047). The difference was more significant for docetaxel 75 mg/m2 patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P = .010; 1-year survival, 37% v 11%; χ2 test, P = .003). Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m2, three of whom died, and in one patient treated with docetaxel 75 mg/m2. Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups. CONCLUSION: Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m2, the benefits of docetaxel therapy outweigh the risks.
引用
- Shepherd FA, Dancey J, Ramlau R, et al. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. J Clin Oncol. 2023. PMID: 37196430. doi:10.1200/JCO.22.02545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。